Cue Biopharma (CUE)
Develops immune-modulating biologics for autoimmune and allergic diseases.
$31.96
vs last close+1.06 (+3.43%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 22.60% | 1.64M shares | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Insiders | 9.43% | 685.0K shares | |
| 10 holders · as of Aug 28, 2026 | |||
| Other | 67.97% | 4.94M shares | |
| remainder | |||
7.26M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (7.26M in the company's Sep 23, 2026 report, 2.63M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
13F, as of Jun 30, 2026
51 holders · 1.64M shares
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 370.7K | 5.10% | Aug 13, 2026 | |
| Driehaus Capital Management LLC | 292.1K | 4.02% | Aug 14, 2026 | |
| Vanguard Capital Management LLC | 161.7K | 2.23% | Aug 13, 2026 | |
| Ikarian Capital, LLC | 104.4K | 1.44% | Aug 14, 2026 | |
| TFG Asset Management GP Ltd | 93.8K | 1.29% | Aug 13, 2026 | |
| Stempoint Capital LP | 67.0K | 0.92% | Aug 14, 2026 | |
| BlackRock, Inc. | 57.8K | 0.80% | Aug 7, 2026 | |
| Adar1 Capital Management, LLC | 55.2K | 0.76% | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Bleichroeder LP | 9.99% | 13G | Mar 21, 2025 | |
| Driehaus Capital Management LLC | 6.96% | 292.1K | 13G | Aug 14, 2026 |
| Shao-Lee Lin | 6.20% | 467.2K | 13D | Aug 21, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Michael Vincent Meluzioofficer: VP, Prin. Accounting Officer | Sale · 3 lots | 5,628 | $30.09 | 48,961 |
| Aug 13, 2026 | Sumita Rayofficer, other: Chief Legal Compliance Officer | Sale · 3 lots | 8,829 | $30.09 | 118,545 |
| Aug 13, 2026 | Shao-Lee Lindirector, officer: Chief Executive Officer | Sale · 3 lots | 18,258 | $28.62 | 705,995 |
| Aug 12, 2026 | Shao-Lee Lindirector, officer: Chief Executive Officer | Sale · 2 lots | 40,000 | $27.10 | 724,253 |
| Jun 1, 2026 | Shao-Lee Lindirector, officer: Chief Executive Officer | Purchase · 2 lots | 136,359 | $3.67 | 136,359 |
| Dec 30, 2025 | Pasha Sarrafdirector | Purchase · 5 lots | 323,857 | $0.3080 | 323,857 |
House and Senate disclosures
Not reported.